Salute e Benessere

Gradient Denervation Technologies Announces Acceptance into FDA’s Total Product…

The FDA’s Center for Devices and Radiological Health (CDRH) launched the TAP Pilot to help expedite patient access to safe and effective, innovative medical devices. To help accelerate development of Gradient’s Denervation System, the TAP Pilot will allow the company to have early and frequent interactions with FDA as well as obtain strategic advice from providers, associations, payors and patient organizations.The Gradient Denervation System is a novel technology intended to treat...
Nasdaq GlobeNewswire
18/06/2025

Embla Medical Recognized for Leadership in Accessibility and International Reach

Forbes Magazine has named Embla Medical to its first-ever global Accessibility 100 list, recognizing the company's history of innovative prosthetics, neuro orthotics and bracing solutions, and high-quality patient care services. The prestigious list recognizes, for the first time, innovators in the field of accessibility for people with disabilities. Forbes Magazine has named Embla Medical to its first-ever globalAccessibility 100list, recognizing the company's history of innovative...
PR Newswire
18/06/2025

Rarecells, Inc. Appoints Dr. Rita Shaknovich to Scientific Advisory Board

NEW YORK and PARIS, June18, 2025(GLOBE NEWSWIRE) -- Rarecells, Inc., a leader in liquid biopsy technology, is pleased to announce the appointment of Dr. Rita Shaknovich to its Scientific Advisory Board. Dr. Shaknovich brings over 20 years of leadership experience across private industry and academia. She has a distinguished track record of building high-performing teams, developing innovative diagnostic tests, establishing world-class laboratory environments, and advancing critical...
Nasdaq GlobeNewswire
18/06/2025

Peer-Reviewed Study in Nature Scientific Reports Demonstrates Non-Invasive Fat…

This publication comes at a time when abdominal obesity is increasingly recognized as a key contributor to cardiovascular disease and metabolic syndrome, both in South Korea and globally. According to the World Health Organization, more than 1 billion people worldwide are living with obesity—a major risk factor for type 2 diabetes, cardiovascular disease, and premature mortality. As obesity rates continue to rise, so does the urgency for safe, effective, and accessible treatment options beyond…
PR Newswire
18/06/2025

Rewind Therapeutics Strengthens Scientific Advisory Board with Leading…

Dr Anja Harmeier, CEO of Rewind Therapeutics, said: "Rewind's mission is to deliver therapies that harness the central nervous system's natural capacity for self-repair. Shiv, Cristina, David, and Roberto have each transformed the way multiple sclerosis is understood and treated within their field. Their expertise will be invaluable as we develop the translational strategy, clinical design, and biomarker validation to support our goal of establishing efficacy and differentiation in the…
PR Newswire
18/06/2025

Bavarian Nordic Announces Sale of Priority Review Voucher for USD 160 Million

COPENHAGEN, Denmark, June 18, 2025– Bavarian Nordic A/S (OMX: BAVA) announced today that it has entered into an agreement to sell its Priority Review Voucher (PRV) for a total cash consideration of USD 160 million. Bavarian Nordic was awarded the PRV in February 2025, following the approval by the U.S. Food and Drug Administration of the chikungunya vaccine, VIMKUNYA™ for prevention of disease caused by chikungunya virus in people 12 years of age and older.Pursuant to a license...
Nasdaq GlobeNewswire
18/06/2025

Camurus' POSITANO study shows treatment effects with CAM2029 in polycystic liver…

"The POSITANO study shows that CAM2029 significantly reduces liver and liver cyst volume compared to placebo while showing improvements in symptoms as assessed by relevant patient reported outcomes", says Dr Joost P.H. Drenth, Professor of Hepatology, Amsterdam University Medical Center and coordinating investigator for the POSITANO study. "There is a high unmet medical need for treatment of patients with polycystic liver disease and the POSITANO study brings hope for our…
PR Newswire
18/06/2025

Oncoinvent Announces Positive Final Data from Phase 1/2a Trial of Radspherin® in…

Reducing peritoneal recurrence in colorectal cancer is critically important because peritoneal metastases are associated with a particularly poor prognosis and significantly lower overall survival compared to other forms of recurrence1. The development of peritoneal metastases is not only linked to worse survival, but also to distressing symptoms, making disease management more challenging and often resulting in treatment interruptions and repeated hospitalizations. Reducing peritoneal...
PR Newswire
18/06/2025

Steri-Tek to boost sterilization capacity of its Texas-based center fivefold…

Louvain-la-Neuve, Belgium, June 18, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and electron beam and X-ray solutions for industrial advanced irradiation, announced today it has signed a contract with Steri-Tek, a growing irradiation services provider, to install a fully-integrated Be Wide X-ray Solution. IBA’s solution will be installed at Steri-Tek’s service center near Dallas-Fort Worth Metro Area, Texas, which was opened in...
Nasdaq GlobeNewswire
18/06/2025

Addex Therapeutics to Release Q1 2025 Financial Results and Host Conference Call…

Geneva, Switzerland, June 18, 2025-Addex Therapeutics(SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will issue its Q1 2025 Financial Results on June 19, 2025. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for...
Nasdaq GlobeNewswire
18/06/2025

Chronic Hepatitis B Market--The US to Have the Lion's Share Among the 7MM…

In most cases, hepatitis B resolves on its own within 1 to 2 months. However, if the infection persists beyond six months, it can become chronic, potentially leading to ongoing liver inflammation, cirrhosis (liver scarring), liver cancer, or liver failure. As of 2024, around 5 million people across the 7MM were living with chronic hepatitis B. Among these, 85% had compensated liver function, while the remaining 15% had progressed to decompensated liver disease. In most cases, hepatitis B...
PR Newswire
17/06/2025

GENFIT: June 17, 2025 Combined Shareholders Meeting Results

All resolutions recommended by the Board of Directors approved (quorum: 27.21%).Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), June 17, 2025-GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the results of the Combined Shareholders Meeting which took place on June 17, 2025. The quorum on first convening amounted to 27.21% and...
Nasdaq GlobeNewswire
17/06/2025

Genomics announces next stage of global roll-out of its predictive clinical tool…

The test is based on polygenic risk scores (PRS), which use sophisticated algorithms to combine information from millions of places in our DNA to give an overall summary of a person's genetic susceptibility to a particular disease. These scores are largely uncorrelated with family history of disease and with clinical risk factors, which means that most people, and their doctors, will have no idea which diseases they are at higher risk of because of their genetics. The test is based on…
PR Newswire
17/06/2025

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; June 17, 2025 –Genmab A/S(Nasdaq: GMAB) will increase its share capital by 32,117 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1:27,396 shares at DKK 1,025.00, 2,790 shares at DKK 1,050.00,150 shares at DKK 1,147.50, 1,557...
Nasdaq GlobeNewswire
17/06/2025

EarlyHealth Group Acquires Corena to Drive $100M Growth in Türkiye’s Life…

This acquisition supports EarlyHealth Group’s strategy to drive a $100 million portfolio of initiatives aimed at globalizing the Turkish pharmaceutical environment.“By combining Corena’s national expertise with our international platform, we are positioned to accelerate government-led export initiatives, strengthen academic-industry collaborations, and advance Türkiye’s role in clinical research and pharmaceutical innovation,” explained Dr. Dan A. Renout, Chief Executive Officer of...
Nasdaq GlobeNewswire
17/06/2025

Press release: Transparency Notification from Shareholders

Transparency Notification from ShareholdersGhent, Belgium – 17 June 2025 – Sequana Medical NV (Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today that it received a transparency notification in relation to the entities listed below, notifying the number of voting rights attached to the shares mentioned next to their name in the table below…
Nasdaq GlobeNewswire
17/06/2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2025

AggregatedpresentationbydayandbymarketStatement of transactions in own shares from June 09th to June 13th 2025 Name of the issuerIdentity code of the issuer(Legal Entity Identifier) Day of the transactionIdentity code of the financial instrument Total daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code)IPSEN549300M6SGDPB4Z94P1109/06/2025FR0010259150 ...
Nasdaq GlobeNewswire
17/06/2025

Transactions with shares and linked securities in Genmab A/S made by managerial…

Company Announcement COPENHAGEN, Denmark; June 17, 2025 –Genmab A/S(Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons.The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish...
Nasdaq GlobeNewswire
17/06/2025

King Faisal Specialist Hospital & Research Centre and Germfree Laboratories…

The new facility will be located at KFSHRC's main campus in Riyadh and will serve as a critical milestone in advancing Vision 2030 and the National Biotechnology Strategy, two national initiatives aimed at transforming the Kingdom into a global hub for life sciences, biomanufacturing, and to become a global biotech hub by 2040. The new facility will be located at KFSHRC's main campus inRiyadhand will serve as a critical milestone in advancing Vision 2030 and the National Biotechnology...
PR Newswire
17/06/2025

Biosimilars Market worth US$72.29 billion by 2035 with 7.5% CAGR |…

Browse in-depth TOC on "Biosimilars Market" Browse in-depth TOC on "Biosimilars Market" 420 - Tables 58 - Figures 391 - Pages By indication,the escalating global burden of cancer, coupled with the high costs associated with biologic therapies, has positioned oncology as the leading segment in the biosimilars market. These biologic medications offer a cost-effective alternative to reference products, thereby improving patient access to crucial treatments. The heightened...
PR Newswire
17/06/2025

Medical Biomimetics Market Share Set to Cross $55.36 Billion by 2030 with 7.6%…

For More Information and To Stay Updated on The Latest Developments in The Global Medical Biomimetics Market Size, Download FREE Sample Pages: https://www.theresearchinsights.com/request_sample?id=8662 For More Information and To Stay Updated on The Latest Developments in The Global Medical Biomimetics Market Size, Download FREE Sample Pages: https://www.theresearchinsights.com/request_sample?id=8662 Market Overview and Growth Trajectory: Medical Biomimetics Market...
PR Newswire
17/06/2025

AI Healthcare Funding Surges as Real-World Rollouts Hit Pharmacies, Hospitals…

According to McKinsey's Global Institute, generative AI isn't just a buzzword — it could deliver between $60 and $110 billion in annual value just within pharma and medical products. Meanwhile, Statista now expects the broader AI healthcare market to explode from $11 billion today to a staggering $188 billion by 2030, reflecting a major shift in how technology is expected to transform patient care, diagnostics, and operational efficiency. According toMcKinsey's Global Institute, generative...
PR Newswire
17/06/2025

Booming Medical Kiosk Market Projected to Hit $3.76 Billion, Globally, by 2030…

For More Information and To Stay Updated on The Latest Developments in The Medical Kiosk Market Share, Download FREE Sample Pages: https://www.theresearchinsights.com/request_sample?id=8647 For More Information and To Stay Updated on The Latest Developments in The Medical Kiosk Market Share, Download FREE Sample Pages: https://www.theresearchinsights.com/request_sample?id=8647 Market Overview and Growth Trajectory: Medical Kiosk Market Growth: According to an exhaustive...
PR Newswire
17/06/2025

U.S. Home Healthcare Services Market to Reach USD 317.9 Billion by 2035, Says…

The U.S. home healthcare services industry continues to expand rapidly as healthcare providers, payers, and patients increasingly recognize the cost-effectiveness and clinical benefits of home-based care delivery. With an aging population of over 88 million Americans expected to be 65+ by 2050, the demand for skilled nursing, rehabilitation, and specialized home healthcare services is driving unprecedented market growth. Medicare and Medicaid reimbursement policies increasingly favor home…
PR Newswire
17/06/2025
Altri  Comunicati